Gilead Sciences: Riding High in Biopharma

Is Gilead Sciences a buy? Find out why this biopharmaceutical giant, known for innovative medicines and a near $140 billion market cap, is making waves. Despite a recent dip from its ten-year high, Gilead's stock is up 22% year-to-date and a whopping 42% over the past year, crushing the Nasdaq. Fueled by strong HIV treatment sales and exceeding Q2 earnings expectations, analysts predict a further 12% growth. Discover why Gilead is outperforming competitors and trending upwards. Hosted on Acast. See acast.com/privacy for more information.